CFDE Data Portal | Search H3C2

	Label	Description
	H3C2 Gene (Entity type)	ENSG00000286522 - H3 clustered histone 2
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE74251 decitabine MCF-7 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

H3C2

ENSG00000286522 - H3 clustered histone 2

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE114883 romidepsin T cell 0 v 4 human up

A Gene Set from LINCS

GSE74251 decitabine MCF-7 0 v 3 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE114883 romidepsin T cell 1 v 4 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human up

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 8 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.